Following review of more than a dozen clinical trials, FDA is alerting
health care professionals about reports of suicidal thinking in children
and adolescents who take Strattera, a drug for attention deficit
hyperactivity disorder. The agency advises close monitoring of patients on
the drug for suicidal thoughts and other unusual changes in behavior,
especially when the dose is changed. More than two million patients have
used Strattera since the drug was first marketed in 2002.

http://www.fda.gov/bbs/topics/NEWS/2005/NEW01237.html

People Who experience mood swings, fear,
voices and visions: each other on the internet
www.peoplewho.org